AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) shares saw strong trading volume on Monday . 983,556 shares were traded during trading, an increase of 181% from the previous session’s volume of 350,082 shares.The stock last traded at $3.78 and had previously closed at $3.73.

A number of research analysts recently commented on the stock. Cowen and Company reiterated a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Monday, May 2nd. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective (down previously from $9.00) on shares of AcelRx Pharmaceuticals in a research note on Tuesday, May 3rd. Seaport Global Securities upgraded shares of AcelRx Pharmaceuticals from an “accumulate” rating to a “buy” rating in a research note on Friday, May 6th. Jefferies Group reiterated a “buy” rating on shares of AcelRx Pharmaceuticals in a research note on Friday, June 10th. Finally, Stifel Nicolaus lowered shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. AcelRx Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $7.63.

The firm has a 50 day moving average price of $3.14 and a 200 day moving average price of $3.35. The firm’s market capitalization is $166.30 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings results on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.22) by $0.02. The company had revenue of $4.53 million for the quarter, compared to analyst estimates of $2.17 million. On average, equities analysts predict that AcelRx Pharmaceuticals Inc. will post ($0.90) EPS for the current fiscal year.

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.